Despite some positive developments in the aerospace and cystoscope programs, the company faces significant challenges. Declining gross margins, increased net loss, and negative EBITDA signal financial strain. The Q&A section revealed uncertainties about equity financing and loan success, which could lead to dilution. The strong demand and production improvements may not offset the immediate financial issues, leading to a negative sentiment and potential stock price decline.